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Background: Information on peripheral neuropathy in children with cystic ﬁbrosis is scanty. The etiology can be multifactorial (micronutrient
deﬁciency, chronic hypoxia, impaired glucose tolerance, immunological, vasculopathic, critical illness).
Methods: Forty ﬁve cystic ﬁbrosis children aged 1–18 years on vitamin E supplementation for at least 6 months underwent detailed neurological
examination, serum vitamin E, vitamin B12, folate, copper levels and detailed nerve conduction studies.
Results: The mean age of the study population was 8.35 years (±4.9 years) with 62.2% being males. Overall 22 out of 45 (48.88%,CI: 33.7–64.2)
had electrophysiological evidence of peripheral neuropathy which was predominantly axonal (86.4%), sensory (50%), and polyneuropathy
(95.45%). There was no signiﬁcant association between status of serum micronutrients and electrophysiological evidence of peripheral neuropathy.
Conclusion: Patients with cystic ﬁbrosis have electrophysiological evidence of peripheral neuropathy (predominantly axonal, sensory and
polyneuropathy). There is signiﬁcant association of higher chronological age with occurrence of peripheral neuropathy.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Axonal; Cystic ﬁbrosis; Micronutrients; Polyneuropathy; Sensory1. Introduction
Cystic fibrosis is an autosomal recessive genetic disease
occurring in 1/3200 Caucasian births [1]. Mutations in
CFTR (Cystic Fibrosis Transmembrane Regulator) result in
channelopathy with impaired sodium and chloride conduc-
tance causing mucosal obstruction of exocrine glands. It is a
multisystem disorder involving pulmonary, gastrointestinal,
endocrine, musculoskeletal, male genitourinary system, joints
and sinuses.
With improvement in quality of care, cystic fibrosis has
evolved into a disease of adults. In the last 45 years dramatic⁎ Corresponding author at: Child Neurology Division, Department of Pediatrics,
All India Institute of Medical Sciences, New Delhi-110029, India.
E-mail address: sheffaligulati@gmail.com (S. Gulati).
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http://dx.doi.org/10.1016/j.jcf.2013.01.005advances in medical management of this disease have resulted in
remarkable improvement in the median age of survival. In 1959
infants with cystic fibrosis lived only for about 6 months,
whereas by 2003 it was around 30 years. Currently the predicted
median survival of patients with cystic fibrosis is greater than
50 years [2].
More than 85% of cystic fibrosis patients show evidence of
malabsorption from exocrine pancreatic insufficiency [3]. This
causes fat malabsorption which leads to multiple nutritional
deficiencies in children with cystic fibrosis. This includes various
fat soluble vitamins. Studies in children with cystic fibrosis have
shown biochemical vitamin E deficiencies in 90–95% of
cases [4–6]. Vitamin E deficiency causes various neurological
complications including peripheral neuropathy [7].
Although there have been attempts over the last 3 decades to
evaluate peripheral nerve dysfunction in patients with cysticby Elsevier B.V. All rights reserved.
755B. Chakrabarty et al. / Journal of Cystic Fibrosis 12 (2013) 754–760fibrosis, none of the studies have come up with a definite and
conclusive evidence. Most of them have less sample size
[8–10]. Very few have tried to study the relation of serum
vitamin E levels with peripheral neuropathy [8]. Vitamin E
deficiency peripheral neuropathy is completely reversible with
vitamin E supplementation.
There are various other nutrients other than vitamin E whose
deficiencies cause peripheral neuropathy viz., thiamine (vitamin
B1), riboflavin (vitamin B2), pyridoxine (vitamin B6), vitamin
B12, folic acid and copper [11]. In this study we reported the
frequency and nature of peripheral neuropathy in cystic fibrosis
patients and relation of this morbidity with serum levels of
micronutrients.
2. Methods
The study was conducted in the Department of Pediatrics, All
India Institute of Medical Sciences and Centre for Promotion of
Nutrition Research & Training with special focus on North-East,
Tribal and Inaccessible population (Indian Council of Medical
Research), New Delhi from January to December 2011. Patients
with confirmed diagnosis of cystic fibrosis, aged 1–18 years, on
vitamin E therapy for at least 6 months were enrolled in the
study. Children with cardiorespiratory instability, known neuro-
muscular disease, family history of inherited muscle/nerve
disease, other systemic illness and on any drugs known to cause
peripheral neuropathy were excluded. Diagnosis of cystic fibrosis
was based on clinical phenotype with two abnormal sweat
chloride values of greater than 60 mEq/L.
With an anticipated prevalence of 50% [10], precision of 15%,
95% confidence, sample size calculated was 45. The study was
approved by the Institutional Ethics Committee.
All patients underwent detailed age appropriate neurological
examination including higher mental functions, speech, cranial
nerves, motor functions, sensory functions (pain, touch, temper-
ature, vibration and proprioception in age appropriate manner)
and cerebellar system.
Serum vitamin E, vitamin B12, folate and copper levels of the
cases were determined at Centre for Promotion of Nutrition
Research& Training with special focus on North-East, Tribal and
Inaccessible population (Indian Council of Medical Research),
New Delhi. Serum vitamin E was measured using HPLC (high
performance liquid chromatography), serum vitamin B12 and
folate were measured using chemiluminescence whereas serum
copper was measured using coupled plasma mass spectrometer.
All enrolled subjects underwent detailed nerve conduction
studies following standard protocol. Motor nerves evaluated
included median, ulnar, tibial and common peroneal nerves, and
sensory nerves evaluated included median, ulnar and sural
nerves. Detailed nerve conduction studies of both sides were
planned. The parameters evaluated were amplitude of compound
muscle action potential of motor nerves, amplitude of sensory
nerve action potential of sensory nerves, conduction velocity of
motor and sensory nerves, distal latency and F waves for motor
nerves and latency for sensory nerves [12,13]. Distal limb
temperature was maintained above 33 °C throughout the study
[14]. During summer the ambient temperature was high enoughto keep the limbs warm, whereas in winter room heaters were
used for the same.
After completion of nerve conduction studies, the values of
the parameters were matched with normal reference values for
age [15]. Abnormal nerve conduction values were classified
either as axonal or demyelinating or unclassified neuropathy.
Axonal neuropathy was defined as reduced (b80% of lower limit
of normal, lower limit of normal being −2.5 standard deviation)/
absent CMAP (Compound Muscle Action Potential)/SNAP
(Sensory Nerve Action Potential) amplitude with or without
low conduction velocity (but not b75% of lower limit of normal)
and prolonged distal latencies (but not N130% of upper limit of
normal). Demyelinating neuropathy was defined as conduction
velocity b75% of lower limit normal, distal latencies N130% of
upper limit of normal, with or without conduction block (at least
50% drop in CMAP amplitude between proximal and distal
stimulation sites), with or without absent or delayed F wave
responses and normal CMAP and SNAP values. If the results
were not fulfilling any of these 2 criteria but were abnormal, the
neuropathy was labeled as unclassified [16,17].
Patients less than 5 years of age were sedated with oral syrup
preparation of Triclophos (20 mg/kg) for electrophysiological
study. Cystic fibrosis being a systemic disease, it is expected that
if neuropathy is present, it would be a generalized disease. The
current recommendation for electrophysiological evaluation of
polyneuropathy is evaluation of at least 1 upper and lower limb
[17,18]. Of the 45 patients, 35 cooperated for complete
evaluation of all 4 limbs, remaining 10 were less than 5 years
of age and so they cooperated for evaluation of 1 upper and lower
limb. Only 14 patients cooperated for F wave response evaluation
as it requires repetitive trains of 10 successive electrical
stimulations.2.1. Statistical analysis
Prevalence of electrophysiologically defined peripheral
neuropathy in cystic fibrosis children aged 1–18 years on
vitamin E therapy for at least 6 months has been expressed as
percentage with confidence interval.
For comparison of the serum level of micronutrients and
baseline clinicodemographic variables in patients with and without
peripheral neuropathy bivariate analysis was done usingWilcoxon
rank sum test, t-test or Fisher exact test wherever applicable.3. Results
3.1. Baseline clinicodemographic profile
Forty five patients attending the Pediatric Chest Clinic,
fulfilling the inclusion criteria and with consenting guardians
were included in the study. Of the 45 cases, 28 (62.2%) were boys
and 17 were girls (37.8%). The mean age at enrolment was
8.35 years (±4.95, range: 1.1–17 years) and the mean age at
diagnosis was 37.2 months (±42.7 months, range: 0.25–
156 months). The mean FEV1, percentage predicted FEV1
(both wherever feasible) and severity of disease score [19] of all
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respectively.
3.2. Clinical neurological profile
None of the patients presented with any symptoms. All
patients underwent age appropriate detailed neurological exam-
ination. Three (6.7%) subjects had subnormal cognition at
enrolment. Ankle hyporeflexia was detected in 7 (15.5%)
patients. Of these, 4 were 6 years or above and also had
abnormal sensory examination, 3 were 5 years or below and
didn't cooperate for detailed sensory examination. Thirty patients
(6 years and above) cooperated for detailed sensory examination.
Of them, 14 (46.7%) patients had abnormality, one impaired
vibration sense and the rest in the form of positive Romberg sign.
Positive Romberg sign is indicative of either peripheral
neuropathy or impaired posterior column sensations. There was
no evidence of cranial neuropathy, focal atrophy or cerebellar
involvement in any of the subjects.
3.3. Electrophysiological profile of peripheral nerves
Overall 22 out of 45 (48.88%, CI: 33.7–64.2) had electro-
physiological evidence of peripheral neuropathy. Nineteen
(86.4%) had axonal and 3(13.6%) had unclassified neuropathy.
None of the subjects had demyelinating type of neuropathy.
Eleven (50%), 9 (40.9%) and 2 (9.1%) had evidence of sensory,
sensorimotor and motor neuropathy respectively (Fig. 1: Scatter
plots showing distribution of amplitudes of sural, median and
ulnar nerves with respect to percentage of lower limit of normal).
Twenty one (95.45%) had evidence of polyneuropathy (Table 1).
3.4. Serum micronutrient profile
Serum levels of vitamin E were normal in all 45 subjects;
however, subnormal values of vitamin B12, folic acid and copper
levels were seen. Overall 8 (36.4%) patients had subnormal levels
of serum micronutrients (3 had both decreased serum vitamin
B12 and folic acid levels, 1 had both decreased copper and
vitamin B12 levels and 4 had isolated vitamin B12 deficiency).
Of these 6 (75%, 3 with both vitamin B12 and folate deficiencies
and 3 with isolated vitamin B12 deficiency) had evidence of
peripheral neuropathy. The mean serum values of micronutrients
were normal (Table 2).
There was no significant difference between the micronutrient-
sufficient and -deficient groups in terms of absence or presence of
peripheral neuropathy (p values of 0.24, 0.233 and 0.488 for
vitamin B12, folic acid and copper respectively), neither was there
any significant difference between mean serum levels of
micronutrients in patients with and without peripheral neuropathy.Fig. 1. (a) Scatter plot showing distribution of sural nerve amplitudes as percentage of
lower limit of normal)/absent amplitudes}. (b) Scatter plot showing distribution of sen
n=80, 7 patients showing decrease (b80% of lower limit of normal)/absent amplitu
percentage of lower limit of normal {−2.5 SD, n=80, 8 patients showing decrease (b
refers to the 80% of lower limit of normal of the sensory nerve amplitude which corHowever subjects with peripheral neuropathy had a lower median
value of serum vitamin B12 and more low normal values (Fig. 2:
Box plot showing serum level of vitamin B12 in patients with and
without neuropathy, Table 3).
3.5. Association of peripheral neuropathy with clinical and
demographic variables
The mean age of patients with peripheral neuropathy was
more than those without peripheral neuropathy and this
difference was statistically significant. However there was no
statistically significant difference in the sex distribution, age at
diagnosis, mean FEV1, percentage predicted FEV1, disease
severity score and mean fasting blood sugar levels in patients
with and without peripheral neuropathy (Table 4).
4. Discussion
The current study has demonstrated that patients with cystic
fibrosis have electrophysiological evidence of peripheral
polyneuropathy with a prevalence of almost 50% which is axonal,
sensory (predominant), sensorimotor or motor. Amongst 30
patients who underwent detailed clinical neurological examination
along with electrophysiological studies, 11 (36.7%) had evidence
of peripheral neuropathy by both clinical (sensory and motor) and
electrophysiological criteria [18]. Three patients had positive
Romberg sign without electrophysiological evidence of neuropa-
thy. One of them had subnormal vitamin B12 levels, which can
cause this abnormality by affecting posterior columns without
causing peripheral neuropathy. Clinical research criteria for distal
symmetrical polyneuropathy were not met as none of the patients
had any clinical evidence of muscle weakness or atrophy [18]. This
finding is compatible with previous studies [8–10].
This study evaluated electrophysiological peripheral neu-
ropathy in cystic fibrosis patients with appropriate sample size
in a detailed and comprehensive manner in a wide age group
range (1–18 years). Serum level of four micronutrients whose
deficiency causes peripheral neuropathy was also determined.
Of the previous 3 cross sectional studies, 2 had done a detailed
electrophysiological evaluation of patients with cystic fibrosis.
Although the prevalence of peripheral neuropathy in this study
is in concordance with them, they had both demyelinating and
axonal characteristics [9,10]. This can be explained by the fact
that the predominant type of neuropathy in systemic diseases is
axonal with occasional segmental demyelination with gener-
alized sensorimotor distribution [20]. The predominant neu-
ropathy in the current study as well as all previous studies has
been sensory with a polyneuropathic picture [8–10].
Previous studies and case reports have documented evidence
of vitamin E deficiency in patients with cystic fibrosis [8,21–23].lower limit of normal {−2.5 SD, n=80, 28 patients showing decrease (b80% of
sory median nerve amplitudes as percentage of lower limit of normal {−2.5 SD,
des}. (c) Scatter plot showing distribution of sensory ulnar nerve amplitudes as
80% of lower limit of normal)/absent amplitudes}. The dashed line in each plot
responds to the threshold below which it is considered to be axonal neuropathy.
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Table 1
Summary of nerve conduction studies in patients with cystic fibrosis.
Nerve Right CMAP
(reduced/absent)
(n=45)
Left CMAP
(reduced/absent)
(n=35)
Motor
Median Nil Nil
Ulnar 8.89% 11.43%
Common peroneal 6.67% 5.72%
Posterior tibial 4.44% 5.72%
Sensory
Median 8.88% 8.57%
Ulnar 8.88% 8.57%
Sural 28.89% 42.85%
Distal motor latency, conduction velocity and sensory latency were normal in
all recorded nerves.
F wave responses: Only 14 patients cooperated for F wave evaluation and all of
them were normal.
Overall 45 patients underwent nerve conduction studies; however, 10 patients
under the age of 5 years didn't cooperate for bilateral evaluation, so all 45
patients underwent nerve conduction of the right side and 35 patients underwent
nerve conduction of the left side.
Reduced CMAP (Compound Muscle Action Potential)/SNAP (Sensory Nerve
Action Potential) was defined as less than 80% of the lower limit of normal for
the age matched value.
Table 2
Serum micronutrient status and their mean levels in patients with cystic fibrosis.
Micronutrients Status of serum levels Mean serum levels
Serum vitamin E Normal in all subjects 1.3 mg/dl (±0.5, 0.6–2.6)
Serum vitamin B12 8/44 (18.18%) subnormal 510.3 pg/ml (±310.5,
150–1134)
Serum folic acid 3/43 (6.93%) subnormal 12.6 ng/ml (±6.7, 2.74–24)
Serum copper 1/43 (2.33%) subnormal 1154.7 μg/dl (±271.93,
590.2–1720)
Serum vitamin E deficiency was defined as b0.5 mg/dl, B12 as b203 pg/ml,
folate as b4 ng/ml and copper as b90 μg/dl.
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already on vitamin E supplementation (400 units/day) at least for
6 months. The recommendation in cystic fibrosis is twice the
recommended daily allowance going up to 200 units/kg/day of
oral vitamin E [11,24]. However on pancreatic enzyme
supplementation, even 5–10 units/kg/day is sufficient [11].
This is the reason why there was no patient with subnormal
serum values of vitamin E deficiency. Subnormal serum vitamin
E levels are seen even in infants with cystic fibrosis [25].
Although children with cholestasis have neurological symptoms
appearing as early as 2nd year of life, malabsorption disorders
show these at the end of 1st and early 2nd decades. Adults with
malabsorption take decades to develop neurological manifesta-
tions [11]. The average age at diagnosis for the current cohort is
around 3 years with no significant difference in patients with and
without peripheral neuropathy. Whether subnormal values of
vitamin E prior to diagnosis can give rise to subclinical
electrophysiological abnormalities is a matter worth investigat-
ing. Treatment with adequate dosage of vitamin E improves the
neurological manifestations by as early as 6 months, but it can
take even more than a year [7]. Moreover, in patients who are
diagnosed at a later age, therapy mostly halts the disease
progression without significantly altering the changes that have
already taken place [26].
Some of the cases with peripheral neuropathy had deficiency
of water soluble micronutrients (vitamin B12 and folic acid). In
addition to peripheral neuropathy one patient with vitamin B12
deficiency also had subnormal cognition. Vitamin B12 deficien-
cy can affect adversely in the form of anemia and neurological
manifestations like myelopathy, neuropathy, impaired cognition
and optic atrophy. Pancreatic proteases are required in the small
intestine for partial degradation of R proteins–cobalamin
complexes (formed in oral cavity and stomach) to enable bindingof cobalamin to intrinsic factor. This implies susceptibility of
cystic fibrosis patients for vitamin B12 deficiency. Thus these
patients should be monitored for the same, given appropriate
dietary advice and treated when indicated. At times vitamin B12
deficiency may not manifest as low serum cobalamin levels.
These patients may have subtle clinical or electrophysiological
evidence of neuropathy. In these cases serum methymalonic acid
and homocysteine levels are useful ancillary investigations as
their levels are elevated [11]. In the current study serum level of
these amino acids was not done, although more low normal
values of serum vitamin B12 were documented in patients with
peripheral neuropathy.
Significant association of increasing chronological age with
peripheral neuropathy as seen in this study has also been
demonstrated in the study by O'Riordan et al. [9]. This implies
that the nerve injury is most probably secondary to factors present
in disease of prolonged duration. One such entity is Cystic
Fibrosis Related Diabetes (CFRD). Although the peak age at
onset is around the end of 2nd decade, there are isolated reports of
onset even in the infancy. However microvascular complications
like neuropathy are usually seen 10 years after the onset of
disease. The current recommendation states screening for these
complications after 5 years of onset of CFRD [27]. In the current
study none of the patients had altered fasting blood sugar values
(maximum age of patient enrolled 18 years) and there was no
significant difference in fasting blood sugar values between
patients with and without neuropathy. The other age dependent
etiology could be peripheral neuropathy secondary to chronic
obstructive pulmonary disease (COPD). COPD appears beyond
the 1st decade of life in cystic fibrosis patients. In adults with
COPD, peripheral neuropathy is associated with increasing age
and degree of hypoxia. In the current study there is no significant
difference between FEV1 (forced expiratory volume in 1 s) and
percentage predicted FEV1 (indicators of disease severity)
between patients with and without neuropathy. However VO2
(volume oxygen maximum) values (marker of hypoxia) were not
available for the current cohort [28].
Other causes for peripheral neuropathy in cystic fibrosis
include immunological and vasculopathy (these correlate more
with periods of disease exacerbation) [10]. None of the cases
were evaluated during a period of acute exacerbation, so
immunological and vascular causes seem less likely. Another
cause for electrophysiological evidence of axonal sensorimotor
neuropathy can be critical illness neuropathy. It is usually seen in
patients who are critically sick (like on ventilator and pressor
Table 4
Comparison of baseline clinicodemographic factors with/without peripheral
neuropathy in patients with cystic fibrosis.
Neuropathy + (22) Neuropathy − (23) p value
Sex (male/female) 1 0.9 1
Age at enrolment 10.3 years (±4.4) 6.5 years (±4.8) 0.01
Age at diagnosis 38.44 months
(±43.82)
42.5 months
(±36.2)
0.5
FEV1 (L) 1.14 (±0.75) 1.19 (±0.7) 0.85
% age predicted FEV1 59. 9 (±24.1) 59.6 (±21.8) 0.97
Disease severity score 63.2 (±8) 63.6 (±7.9) 0.85
Blood sugar (fasting, mg%) 87.2 (±7.5) 85.7 (±5.6) 0.5
Fig. 2. Box plot depicting serum vitamin B12 levels in patients with (n=22) and
without peripheral neuropathy (n=23). The peripheral neuropathy group
showing a lower median value and consequently more low normal values of
serum vitamin B12.
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of peripheral neuropathy can persist in such patients for up to
5 years [29]. However in the current study only one patient had
requirement of ventilator and pressor support in recent past.
Strength of the current study includes documentation of serum
levels of common micronutrients and their relation to neuropathy
in patients with cystic fibrosis in a reasonable sample size. The
patients with and without peripheral neuropathy were also
compared with regard to fasting blood sugar values, FEV1 and
FEV1% and disease severity scores.
The current study has limitations in the form of it being a
single time point study, both temporal evolution of the disease
and follow up studies following micronutrient supplementation
were not done. Other water soluble micronutrients like thiamine,
riboflavin and pyridoxine that are associated with peripheral
neuropathy were not estimated. During planning of the study it
was not considered, as usually deficiency of water soluble
vitamins does not happen in patients with cystic fibrosis.
Although fasting blood sugar values for patients were available,
glucose tolerance test was not planned which could have hintedTable 3
Comparison of serum levels of micronutrients with/without peripheral neuropathy
in patients with cystic fibrosis.
Neuropathy present
(22)
Neuropathy absent
(23)
p value
Vitamin E 1.2 mg/dl
(±0.3,
0.6–2.3)
1.4 mg/dl
(±0.55,
0.6–2.6)
0.44
Vitamin B12 533.5 pg/ml
(±336.7,
150–1134)
527.2 pg/ml
(±291.7,
174–1124)
0.64
Folic acid 12 ng/ml
(±7.2, 2.7–24)
11.5 ng/ml
(±6.2 4.9–24)
0.86
Copper 1124.6 μg/dl
(±246.5,
685.2–1688)
1262.9 μg/dl
(±304.4,
590.2–1720)
1.64towards a cause for indolent subclinical neuropathy. Evaluation
of concomitant serum methylmalonic acid and homocysteine
levels could have increased the yield of vitamin B12 deficiency
(particularly those with low normal values) in patients with
neuropathy. Detailed pulmonary function test with comparison of
VO2 in patients with and without neuropathy would have
highlighted the effect of recurrent hypoxia.
To conclude, patients with cystic fibrosis have electrophysi-
ological evidence of peripheral polyneuropathy which is
predominantly axonal and can be sensory, motor or sensorimotor.
There is significant association of higher chronological age with
occurrence of peripheral neuropathy. This opens up future
implications for research. Follow-up studies evaluating the
evolution of the process, minimally invasive punch skin biopsy
examining the dermal myelinated and unmyelinated nerve fibers
to study the cellular and molecular basis [30], intervention studies
like prescribing micronutrients and then following up the status
of neuropathy, and correlation of glucose tolerance and
pulmonary function tests with peripheral neuropathy can open
up fresh horizons and create newer dimensions to the entire
concept.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2013.01.005.References
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